Arizona, May 1, 2024 – Aspiro Therapeutics proudly highlights the foundational work of co-founder Dr. Julie Ledford, whose research, funded by a Flinn Foundation Seed Grant awarded in June 2023, played a key role in Aspiro’s formation and scientific direction. Awarded through her role at the University of Arizona, Dr. Ledford’s research focuses on innovative therapeutic strategies for respiratory health, specifically targeting mechanisms central to obstructive lung diseases like asthma and COPD.
The Flinn Foundation Seed Grant supported essential research supporting Aspiro’s mission to develop disease-modifying therapies for complex lung conditions. Dr. Ledford’s expertise and dedication to advancing health care solutions for patients with unmet respiratory needs have been instrumental in shaping Aspiro’s approach to therapeutic development.
“This foundational research, made possible by the Flinn Foundation’s support, directly influenced the formation of Aspiro and its vision for respiratory innovation,” said James Lovgren, CEO of Aspiro Therapeutics. “Dr. Ledford’s work has provided us with the scientific insight needed to address the underlying mechanisms of obstructive lung diseases, giving new hope to patients and redefining therapeutic possibilities in this field.”
About the Flinn Foundation
The Flinn Foundation is a philanthropic grant-making organization dedicated to improving the quality of life in Arizona to benefit future generations. Founded in 1965, the foundation provides funding for initiatives in the fields of bioscience, health care, and education, with a mission to drive advancements that strengthen Arizona’s biomedical research ecosystem. Through its seed grant program, the Flinn Foundation supports high-potential research projects and innovators working to transform health care and improve patient outcomes.
